Table 1.
Clinical or pathological features | All cases | n (%) | Total CIT (%) | Total Dijon (%) | P value | MSS CIT (%) | MSS Dijon (%) | P value | MSI CIT (%) | MSI Dijon (%) | P value |
---|---|---|---|---|---|---|---|---|---|---|---|
Gender | |||||||||||
Female | 826 | 361 (44) | 189 (44) | 172 (44) | 0.97 | 156 (43) | 130 (40) | 0.49 | 33 (49) | 42 (64) | 0.13 |
Male | 465 (56) | 244 (56) | 221 (56) | 210 (57) | 197 (60) | 34 (51) | 24 (36) | ||||
Age (years)1 | 826 | 826 | 69 [24–96] | 73 [33–95] | 1.6 × 10−6 | 69 [25–96] | 73 [36–95] | 0.00021 | 74 [24–92] | 80 [33–91] | 0.0016 |
Tumor location2 | |||||||||||
Distal | 826 | 472 (57) | 249 (58) | 223 (57) | 0.88 | 234 (64) | 214 (65) | 0.74 | 15 (22) | 9 (14) | 0.28 |
Proximal | 354 (43) | 184 (42) | 170 (43) | 132 (36) | 113 (35) | 52 (78) | 57 (86) | ||||
TNM stage | |||||||||||
I | 826 | 76 (9) | 33 (8) | 43 (11) | 0.0052 | 25 (7) | 35 (11) | 0.015 | 8 (12) | 8 (12) | 0.23 |
II | 431 (52) | 211 (49) | 220 (56) | 175 (48) | 176 (54) | 36 (54) | 44 (67) | ||||
III | 319 (39) | 189 (44) | 130 (33) | 166 (45) | 116 (35) | 23 (34) | 14 (21) | ||||
Adjuvant CT | |||||||||||
No | 823 | 540 (66) | 257 (59) | 283 (72) | 0.00014 | 203 (55) | 222 (68) | 0.00071 | 54 (82) | 61 (92) | 0.12 |
Yes | 283 (34) | 175 (41) | 108 (28) | 163 (45) | 103 (32) | 12 (18) | 5 (8) | ||||
Associated syndrome | |||||||||||
FAP | 806 | 1 (0) | 0 (0) | 1 (0) | 0.0087 | 0 (0) | 1 (0) | 0.96 | 0 (0) | 0 (0) | 0.0002 |
Lynch syndrome | 22 (3) | 18 (4) | 4 (1) | 0 (0) | 0 (0) | 18 (35) | 4 (6) | ||||
None | 783 (97) | 395 (96) | 388 (99) | 362 (100) | 326 (100) | 33 (65) | 62 (94) |
MSS, microsatellite stable; MSI, microsatellite instable; CT, chemotherapy; FAP, familial adenomatous polyposis.
Median [range].
Proximal colon included cecum, ascending colon, hepatic flexure, and transverse colon, and distal colon included splenic flexure, descending, and sigmoid colon.